Computational Physiology in Medical Device Arena: The New Concept of Mechanical Biocompatibility
Monday, March 4, 2019
11:00 – 12:00 p.m.
Higgins Laboratories 102
Research Presentation Abstract
Cardiovascular disease remains as the leading cause of morbidity and mortality due to aging populations and risk factors associated with life habits. As the most frequently practiced therapy in cardiology, percutaneous intervention has made great strides because technological innovation has marched in lock step with advances in biology know-how, computational science, and engineering. Mechanistic understanding of pathophysiology and data-driven design/optimization of medical devices have enhanced the therapy and reduced clinical costs and events.
The evolution of personalized digital medicine towards enhanced prevention techniques, diagnosis, and therapy is promisingly feasible nowadays due to substantial advances in imaging modalities, mathematical models, and computational power. Moreover, there is an increasing interest to use subject-specific computational models to complement experimental research in medicine. The ultimate goal for these engineering tool kits is to be routinely used in real-time clinical platforms and hopefully adopted by regulatory officials as in silico clinical trials. Toward this end, there is a clear need to integrate ideas, form close collaborations between scientists, engineers, and clinicians, and develop rigorous tools for modeling, analysis, and synthesis of complex biological systems. Our research agenda contributes to fulfill this vision by addressing emerging problems from new angles, incorporating powerful computational tools, and capitalizing on the synergy between mechanical engineering, translational medicine, and informatics. Our new perspective assesses the contextual biocompatibility of medical implants relative to mechanical environment to which they are exposed. To highly optimize contemporary interventional practices, advances in mechanical design, drug use, and deployment strategies are required along with biomaterial innovations. This novel approach has created both challenges and opportunities to further improve clinical performance. The aim of this talk is to introduce this vision, discuss the achievements and challenges, and introduce our future research agenda. The focus would be to briefly discuss how advanced medical devices are expected to perform (mechanically, in particular) rather than merely exist in complex environment of living substrates to dictate clinical efficacy and safety..
Dr. Farhad Rikhtegar Nezami, is currently affiliated as a postdoctoral associate and project leader at Harvard-MIT Biomedical Engineering Center, located at the Institute for Medical Engineering and Science of MIT. He has got his PhD in Mechanical engineering from ETH Zurich, where he conducted research on hemodynamics and drug transport in stented coronary arteries. He completed his master's and bachelor's degrees at Sharif University of Technology and Amirkabir University of Technology in Tehran, respectively. Dr Rikhtegar Nezami’s research interests revolve around human pathophysiology, successful translation of preclinical experiments to clinical practices, design and optimization of medical devices, and developing engineering platforms to drive progress from the laboratory bench and computational toolkit to the patient's bedside.